tirzepatide injection schedule Best day to take tirzepatide: choosing your weekly Comprehensive Guide To Subcutaneous Self-Injection

F.ForthommeB.GoffC

This specific product is not presented for human consumption, self-administration, therapeutic, diagnostic, veterinary or clinical use

Much of the discussion around weight regain after discontinuation of GLP-1 or GLP-1/GIP therapy focuses on what happens but not enough on how the trials were designed

2025 Jul 2;16:1551843

CMS requires providers to confirm the medication is used for weight reduction along with ongoing lifestyle changes, and that the individual met one of the following when treatment started: BMI 35 BMI 30 with conditions like HFpEF, uncontrolled hypertension, or CKD (stage 3a+) BMI 27 with prediabetes or established cardiovascular disease (e.g., prior MI, stroke, PAD) One important note: this coverage will operate outside of typical Part D plans, so the approval process will look different

JDC 34:107520